Paysign, Inc. (NASDAQ:PAYS – Get Free Report) major shareholder Daniel Spence sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $3.60, for a total transaction of $360,000.00. Following the sale, the insider now directly owns 9,090,000 shares of the company’s stock, valued at approximately $32,724,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Paysign Stock Down 1.8 %
NASDAQ:PAYS opened at $3.60 on Friday. The company has a market cap of $190.72 million, a PE ratio of 27.69 and a beta of 0.96. The business’s 50 day moving average is $4.50 and its two-hundred day moving average is $4.39. Paysign, Inc. has a 52 week low of $1.67 and a 52 week high of $5.59.
Paysign (NASDAQ:PAYS – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.01 EPS for the quarter. Paysign had a net margin of 14.42% and a return on equity of 32.55%. The firm had revenue of $14.33 million during the quarter, compared to the consensus estimate of $14.07 million. As a group, sell-side analysts expect that Paysign, Inc. will post 0.21 EPS for the current fiscal year.
Institutional Investors Weigh In On Paysign
Analyst Upgrades and Downgrades
Separately, Barrington Research reissued an “outperform” rating and set a $7.00 price objective on shares of Paysign in a report on Friday, June 28th.
Read Our Latest Report on Paysign
About Paysign
Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.
See Also
- Five stocks we like better than Paysign
- 3 Grocery Stocks That Are Proving They Are Still Essential
- When Is the Best Time to Invest in Mutual Funds?
- Using the MarketBeat Stock Split Calculator
- Is NVIDIA Stock in a Correction or Consolidation?
- Top Stocks Investing in 5G Technology
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.